The Efficacy of Pro- and Anticoagulant Therapy in Plasma of Patients with Cirrhosis undergoing Orthotopic Liver Transplantation

The Efficacy of Pro- and Anticoagulant Therapy in Plasma of Patients with Cirrhosis undergoing Orthotopic Liver Transplantation - EPAC-OLT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42693

Enrollment

Registered

2015-08-20

Start date

2015-09-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bleeding Thrombosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Orthotopic Liver Transplantation for cirrhosis at the UMCG Age >18 years Signed informed consent

Exclusion criteria

Exclusion criteria: Acute liver failure Documented history of hereditary thrombophilia Use of vitamin K antagonists Transfusion of blood products (

Design outcomes

Primary

Measure	Time frame
Thrombin generation by Calibrated Automated Thrombinography.	—

Secondary

Measure	Time frame
Other study parameters are individual coagulation factors, Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (APTT), Fibrinogen, Platelet count and Hemoglobin (Hb). Moreover, indicators of liver function such as Gamma-Glutamyl Transpeptidase (GGT), Asparate Aminotransferase (ALT) Alanine Transaminase (AST), ammonia (NH3), alpha1 antitrypsin and ceruloplasmin are study parameters.	—

Measure

Time frame

Other study parameters are individual coagulation factors, Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (APTT), Fibrinogen, Platelet count and Hemoglobin (Hb). Moreover, indicators of liver function such as Gamma-Glutamyl Transpeptidase (GGT), Asparate Aminotransferase (ALT) Alanine Transaminase (AST), ammonia (NH3), alpha1 antitrypsin and ceruloplasmin are study parameters.

—

Countries

Netherlands

Outcome results